Transforming Industry Engagement at the University of Bristol

Lead Research Organisation: University of Bristol

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.  The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities.  This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes.  Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.

Publications

10 25 50
 
Description Academy of Medical Sciences Springboard Scheme (Lavinia Paternoster)
Amount £100,000 (GBP)
Funding ID SBF003\1094 
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 01/2019
 
Description BBSRC IPA (Emma Robinson)
Amount £573,135 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2016 
End 12/2020
 
Description BBSRC IPA (Richard Apps)
Amount £411,555 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description Innovate UK Investment Accelerator (Adam Perriman)
Amount £150,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2018 
End 02/2019
 
Description Innovate UK KTP with UCB (Moin Saleem)
Amount £150,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2019 
End 03/2021
 
Description NIHR Knowledge Mobilisation Fellowship
Amount £267,592 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2018 
End 05/2020
 
Description People Exchange Project with BT and Nokia (Helen Baxter) 
Organisation BT Group
Country United Kingdom 
Sector Private 
PI Contribution This is a unique opportunity for researchers working in the area of urgent care within the Centre for Academic Primary Care (CAPC) to understand more about the implications of the involvement of the telecommunications industry and how we may be able to work in partnership with them to improve healthcare in the broadest sense. Within the department we have very little knowledge of this industry and how the technologies are designed and piloted, which has prevented us from being able to interact with such industry partners. Potential areas for collaboration could be in the use of sensors for diagnosis, pre and post treatment in terms of how data can be managed and collected. How urgent care clinicians use existing technology and how this could be improved upon using by understanding some of the advances coming on to the market. There may be also potential to undertake small studies using our research methodologies to inform the development of some of the technologies being considered or feedback the research evidence to date.
Collaborator Contribution EE has been selected by the Home Office to provide Britain's Emergency Services with a resilient national mobile network, giving 300,000 critical emergency workers access to 4G voice and data for the first time. Thus the telecommunications industry is now a pivotal part of urgent care system across the country. The Government's £1 billion Emergency Services Mobile Communications Programme (ESMCP) will ensure that Britain is a world leader in Emergency Services communications, and a 4G pioneer. EE already has the UK's biggest and most mature 4G network, and will expand coverage and enhance resilience to meet the Emergency Services' critical communications requirements. One of the applications that the new network will enable for Britain's Emergency Services is for an ambulance crew sending vital patient data on to the hospital to allow staff to make the best preparations for a patient's arrival. British Telecom has recently acquired EE and will be supporting the network for the Emergency services. This company is keen to understand where the telecommunications industry can further assist in the area of healthcare and is keen to work with university partners to understand better the evidence on what the major challenges are. Nokia is a global leader in telecommunication technologies and includes the research and innovation company Bell Labs with UK bases in Cambridge and Dublin. Nokia is currently developing and testing technologies that have the potential to transform how we communicate with each other and how we share information.
Impact NIHR Knowledge Mobilisation Fellowship for Helen Baxter
Start Year 2017
 
Description People Exchange Project with Brunelcare (Melanie Chalder) 
Organisation Brunelcare
PI Contribution In Bristol, ageing 'well' is a strategic priority for local commissioners, managers, researchers and healthcare providers. A number of NHS initiatives to improve care, quality of life and health outcomes for older adults and their families / carers already exist e.g. the use of admission avoidance schemes and early discharge services as well as dementia, falls and chest clinics. Similarly, a number of community-based, social care and voluntary sector services aimed at older adults also exist e.g. intermediate care teams and Age UK. However, the number of older adults who live with poor mental or physical health or experience unwanted social isolation continues to be unacceptably high. Support services for this particular population sub-group - whether related to health or social care - are of variable quality and are often fragmented. What is more, the longer-term costs of having so many unwell older individuals using NHS and other resources remains unknown. It is also clear that the topic of living well in older age is a priority area for the MRC and that considerable resource is being invested in research to understand how and why health and wellbeing varies within and between populations and across the life course, and how the health of the public can be improved through carefully targeted interventions.
Collaborator Contribution The project aimed to explore some of the issues that affect service provision to older people in the South West and to consider how service providers might improve the range, quality, availability and cost-effectiveness of care on offer. I believe that exploratory conversations with key staff at Brunelcare, observation of their facilities and working practices as well as familiarisation with their business model could well 'unlock' some of the barriers experienced by academic healthcare scientists - both in terms of better understanding service delivery but also in terms of working with non-academic, non-NHS partners. I feel Brunelcare will make a strong industry partner for this specific project as they cover a wide geographic area (Somerset, Bristol and South Gloucestershire), offer a range of provision to their clients (care, support and residential services) and, perhaps most importantly, are enthusiastic about the prospect of collaboration with academia.
Impact - £18,436 funding from Avon Primary Care Research Collaborative for RCF project, 'Medication optimisation in older patients with problematic polypharmacy' - £2,000 GW4 Crucible award for the Research Fellow, resulting in specialist training in collaborative working
Start Year 2016
 
Description People Exchange Project with GSK (Venexia Walker) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution The aim of this project is to consider the relationship between Mendelian randomization estimates of effect and those we observe in practice at the first part of the drug pathway, i.e. at the cellular level. For example, in the case of statins, we would like to investigate how the Mendelian randomization estimates of their effect correspond to the percentage inhibition of HMGCR observed in preclinical and early phase clinical trials. It is hoped that by considering intermediate steps on the drug pathway, we will be able to fully understand the relationship between Mendelian randomization estimates of effect and observed drug effects in the future.
Collaborator Contribution This project will consider data on up to half a dozen approved drugs in order to interrogate the relationship between their effect at a cellular level and their effect as estimated by Mendelian randomization. GSK provided access to those drugs.
Impact £400,000 funding from GSK for Senior Research Associate
Start Year 2016
 
Description People Exchange Project with Sanofi (Tom Richardson) 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution The team are developing an analytical pipeline to take a candidate gene or genomic region of interest and inform the user on its role in disease aetiology using publically available data and ALSPAC data
Collaborator Contribution Sanofi will make available it's current pipeline of drug development trials to test the analytical pipeline described above.
Impact Sanofi have funded two collaborative projects to a value of £340,000
Start Year 2016
 
Description People Exchange Project with UCB (Moin Saleem) 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution A BBSRC case award between UCB and the University gave rise to a 3-cell, human glomerular fibrosis model that simulates the disease uniquely.
Collaborator Contribution UCB aims to revolutionise preclinical drug discoveries by utilising this functional cell organoid system that (when exposed to clinically relevant disease stimuli) simulates fibrosis much better than current industry standards. A people exchange project enabled the first steps to be taken within that objective.
Impact £1M investment from UCB into the National Unified Renal Translation Research Enterprise (NURTuRE) a kidney biobank for chronic kidney disease and nephrotic syndrome UCB extended the exchange project by 6 months with a value of £30,000 £150,000 award from Innovate UK's KTP scheme
Start Year 2016
 
Description Travel award to visit Evotec (Moin Saleem) 
Organisation Evotec
Country Germany 
Sector Private 
PI Contribution The mainstay of Bristol Renal's research are specialised resources to investigate these, including state-of-the-art imaging techniques, in vivo models and potential in vitro, in vivo and ex vivo screening assays to help identify novel therapeutic targets.
Collaborator Contribution The cornerstone of Evotec's in vitro and in vivo pharmacology function is disease and target biology expertise coupled with state-ofthe- art technology platforms. Evotec have a strong focus on acute and chronic kidney disease and diabetic nephropathy.
Impact - £500,000 investment from Evotec into the National Unified Renal Translation Research Enterprise (NURTuRE) unique kidney biobank for chronic kidney disease and nephrotic syndrome covering England, Scotland and Wales. - A strategic collaboration on microfluidics technology including induced pluripotent stem cell ("iPSC") differentiation to accelerate the discovery of novel drugs to treat kidney diseases called NEPLEX. The financial value of this collaboration is confidential.
Start Year 2017
 
Description Travel award to visit GSK Vaccines (Darryl Hill) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Pathogenic neisserial species, Neisseria meningitidis and N. gonorrhoeae, cause a range of focal and disseminated infections which lead to serious morbidity and all too often morality. Unlike the situation with other serogroups of meningococci, the lack of immune response to the capsule of serogroup B strains, the most prevalent meningococcus serogroup in Europe and America, has led to development of Bexsero® by Novartis/GSK Vaccines, a protein- and outer membrane vesicle-based vaccine. Whilst significant progress has been made towards the eradication of meningococcal disease it is accepted that no current vaccine can completely prevent all forms of the disease due to the variable nature of the antigens in existing vaccines. To this end our research group has identified two meningococcal surface proteins, Msf and Opc which enable bacteria to bind to vitronectin and in doing so avoid killing by the immune system. Our studies have shown that immunising with recombinant form of the vitronectin binding region of both Msf and Opc leads to the production of antibodies which are both function blocking and bactericidal. Our current studies are examining the population structure of Msf and Opc in order to inform vaccine design. Strains within N. gonorrhoeae are even more variable than those within N. meningitidis meaning we are still many years from a gonococcal specific vaccine, a concern given the evolution of multi-drug resistant gonococci. Given that Bexsero® contains antigens which are also expressed by gonococci it is possible that this vaccine may offer some cross protection against gonococcal infection.
Collaborator Contribution to explore the possibility of establishing 2 arms of collaborative research, the first being the inclusion of our vaccine targets in the next generation meningococcal vaccine under development at GSK Vaccines, Siena. Second, we are building our gonococcal research programme in Bristol and would like to run a study evaluating the impact of Bexsero® on gonococcal carriage and disease.
Impact GSK have co-funded two PhD studentships. Value is confidential
Start Year 2017
 
Description Biomedical and Health Industry Day 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact - This showcase event contributed towards the developing culture change in our academic community in relation to industry engagement. It also demonstrated the rich translational potential of our health research to prospective industry partners. - 147 delegates attended including 54 from industry, investors and funders The event directly led to the following collaborations: o £573,135 BBSRC IPA with Boehringer Ingelheim; PI Emma Robinson o £411,555 BBSRC IPA with Takeda; PI Richard Apps Bristol Bridge Bridging the Gaps between Academia, Translation and Commercialisation £1,056.25 2016 award - The projects funded by our EPSRC BristolBridge project on
Year(s) Of Engagement Activity 2016